SCHEMBL7664754

SCHEMBL7664754

CC(=O)On1c(=O)c(-c2cn(Cc3cccc(CN)n3)c3ccccc23)nc2cc3c(cc21)CCC3

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 1/20 0.34
CHRM1 P11229 1/20 0.32
USP2 O75604 3/20 0.31
CYP1A2 P05177 3/20 0.31
CYP3A4 P08684 3/20 0.31
CYP2C9 P11712 3/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP2C19 P33261 1/20 0.31
CLK4 Q9HAZ1 1/20 0.31
CASP1 P29466 2/20 0.31
CASP7 P55210 2/20 0.31
CA12 O43570 2/20 0.31
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
CA9 Q16790 2/20 0.31
LMNA P02545 1/20 0.31
TSHR P16473 1/20 0.31
PDE4B Q07343 5/20 0.31
PDE4D Q08499 5/20 0.31
PDE4A P27815 4/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7656864 0.98 ACKR3 (0.34) ACKR3CHRM1USP2CYP1A2CYP3A4
SCHEMBL7664799 0.91 PDE4A (0.37) CHRM1CA12CA1CA2CA9
SCHEMBL7663917 0.90 PDE4A (0.38) CHRM1CA12CA1CA2CA9
SCHEMBL7662878 0.90 ACKR3 (0.36) ACKR3CHRM1USP2CYP1A2CYP3A4
SCHEMBL7660922 0.89 PDE4A (0.37) USP2CYP1A2CYP3A4CYP2C9CASP1
SCHEMBL7652540 0.88 PDE4A (0.37) USP2CYP1A2CYP3A4CYP2C9CASP1
SCHEMBL7665495 0.85 CAMK2D (0.41)
SCHEMBL8516671 0.85 CAMK2D (0.35) ACKR3CHRM1USP2CYP1A2CYP3A4
SCHEMBL7663936 0.85 CAMK2D (0.39) USP2CYP1A2CYP3A4CYP2C9ALDH1A1
SCHEMBL7664149 0.84 CAMK2D (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6458792-B1 MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. ASTRAZENECA AB (SE) 2002-10-01 US disclosed
EP-1071683-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2001-01-31 EP disclosed
WO-1999046264-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 1999-09-16 WO disclosed